Olympus, Cangen Biotechnologies to Expand Joint Development of Molecular Diagnostic Test for Early Lung Cancer Detection.Tokyo, Japan, Jan 6, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - On January 6, Olympus and Cangen Biotechnologies jointly announced that they have agreed to expand their ongoing research collaboration to develop a hybrid DNA-based and protein-based diagnostic test for use in the early detection of lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . Specifically, the two companies will begin a clinical study in Asia to evaluate and finalize fi·nal·ize tr.v. fi·nal·ized, fi·nal·iz·ing, fi·nal·iz·es To put into final form; complete or conclude: "They have jointly agreed ... the DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. markers this spring. They aim to obtain approval from the US Food and Drug Administration in two years. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion